Ferinject approved by Health Canada for the treatment of iron deficiency anaemia in adult and paediatric patients and iron deficiency in adult patients with heart failure

CSL Vifor

19 March 2024 - CSL Vifor today announced that Health Canada has authorised Ferinject (ferric carboxymaltose) for the intravenous treatment of iron deficiency anaemia in adult and paediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association (NYHA) class II/III to improve exercise capacity.

Ferinject has now received marketing authorisation in 87 countries worldwide.

Read CSL Vifor press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Canada